These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10220573)

  • 1. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers.
    Maurer BJ; Ihnat MA; Morgan C; Pullman J; O'Brien C; Johnson SW; Rasey JS; Cornwell MM
    Mol Pharmacol; 1999 May; 55(5):938-47. PubMed ID: 10220573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
    Frankel A; Buckman R; Kerbel RS
    Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
    Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
    Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.
    Gatti L; Supino R; Perego P; Pavesi R; Caserini C; Carenini N; Righetti SC; Zuco V; Zunino F
    Cell Death Differ; 2002 Dec; 9(12):1352-9. PubMed ID: 12478472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and radiation response of cells grown in macroporous gelatin microcarriers (CultiSpher-G).
    Rasey JS; Cornwell MM; Maurer BJ; Boyles DJ; Hofstrand P; Chin L; Cerveny C
    Br J Cancer Suppl; 1996 Jul; 27():S78-81. PubMed ID: 8763852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
    Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
    Jin Z; Guan T; Li S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
    Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
    Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
    Hawkins DS; Demers GW; Galloway DA
    Cancer Res; 1996 Feb; 56(4):892-8. PubMed ID: 8631030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
    Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
    Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental study on resistance to cisplatin and taxol in human ovarian cancer SKOV3ip1 multicellular aggregates].
    Chen J; Feng Y; Zhou X
    Zhonghua Fu Chan Ke Za Zhi; 2001 Aug; 36(8):489-92. PubMed ID: 11758187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Roles of p53 in chemotherapy of glioblastoma].
    Ikeda J
    Hokkaido Igaku Zasshi; 2000 Sep; 75(5):299-314. PubMed ID: 11070791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.